Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

Regulators Recommend Suspension of Weight Loss Drug Acomplia

Posted by Chrissie Cole
Monday, October 27, 2008 11:58 AM EST
Category: Major Medical
Tags: Sanofi-Aventis, Acomplia, Rimonabant, Diet Drugs, Weight Loss, Obesity, Phen-Fen, PPH,

LEARN MORE

IMAGE SOURCE: © Wikimedia Commons/ Rimonabant Chemical Structure / Pngbot

European regulators recently ordered Sanofi-Aventis to withdraw its weight-loss drug Acomplia across the Europe Union, sending a crippling blow to the French pharmaceutical group.

After reviewing data that suggests obese and overweight patients had twice the risk of developing psychiatric disorders such as depression, anxiety and aggression, than those on a placebo, The European Medicines Agency (EMEA) determined the benefits no longer outweighed the risks for the drug – generically known as rimonabant.

A U.S. advisory panel declined approval of the drug last year.

Acomplia was the first promising drug to tackle the growing epidemic of obesity, since Phen-Fen, a combination treatment prescribed more than six million times before it was recalled for deadly side effects in 1997.

The FDA discovered that the drug combination in Phen-Fen was responsible for an alarmingly high occurrence of heart valve defects and a deadly condition known as primary pulmonary hypertension (PPH).

PPH is a disease caused by narrowing of certain blood vessels in the heart and lungs. A statistically significant number of persons who took Phen-Fen also suffered from PPH (reportedly 1 in 25,000 who used Phen-Fen for more than 3 months).

Acomplia was the first of a class of drugs called selective cannabinoid receptor CB1 antagonists that work by blocking hunger signals in the brain, thereby suppressing the appetite. Earlier this month, Merck & Co. said its experimental treatment taranabant, in the same class of drugs, won't make it to market because it causes depression and irritability in users.

Marketed in 18 EU countries since 2006, Acomplia was to be used alongside diet and exercise and to treat obese or overweight patients has shown moderate effectiveness.

Between June and August of this year, five patients taking Acomplia as part of a clinical trial committed suicide. One person that was taking the placebo committed suicide.

The company said they would comply with the request to temporarily withdraw marketing the drug and added it will provide additional documents from the trials to assists with the re-evaluation of Acomplia. 700,000 people worldwide had used the drug. #


No Comments

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address

Subscribe

RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes